Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.55 |
| ▸ | FURIN | P09958 | 9/20 | 0.52 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.52 |
| ▸ | NPY1R | P25929 | 3/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | NRP1 | O14786 | 1/20 | 0.43 |
| ▸ | NPY4R | P50391 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29595648 | 0.91 | FURIN (0.56) | CHRM2CHRM4CHRM1SIRT5FURIN | |
| SCHEMBL29393341 | 0.90 | SIRT5 (0.64) | CHRM2CHRM4CHRM1SIRT5FURIN | |
| SCHEMBL14117893 | 0.89 | CHRM2 (0.69) | CHRM2CHRM4CHRM1SIRT5NPY1R | |
| Etelcalcetide SCHEMBL29647613 | 0.81 | SIRT5 (0.49) | CHRM2CHRM4CHRM1SIRT5FURIN | |
| Trifluoroacetic Acid SCHEMBL31741398 | 0.81 | SIRT5 (0.59) | CHRM2CHRM4CHRM1SIRT5FURIN | |
| SCHEMBL20548856 | 0.81 | SIRT5 (0.53) | CHRM2CHRM4CHRM1SIRT5FURIN | |
| Etelcalcetide SCHEMBL30221949 | 0.81 | SIRT5 (0.48) | CHRM2CHRM4CHRM1SIRT5FURIN | |
| SCHEMBL13337947 | 0.79 | CHRM2 (0.64) | CHRM2CHRM4CHRM1SIRT5FURIN | |
| SCHEMBL29546257 | 0.79 | CHRM2 (0.64) | CHRM2CHRM4CHRM1SIRT5FURIN | |
| SCHEMBL16748402 | 0.79 | CHRM2 (0.68) | CHRM2CHRM4CHRM1SIRT5CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361280-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250320471-A1 | Method for Producing Compounds, Method for Producing Compound Library, Compound Library, and Screening Method | UNIV TOKYO (JP) | 2025-10-16 | — | — | US | disclosed |
| EP-4431519-A1 | METHOD FOR PRODUCING COMPOUNDS, METHOD FOR PRODUCING COMPOUND LIBRARY, COMPOUND LIBRARY, AND SCREENING METHOD | The University of Tokyo (JP) | 2024-09-18 | — | — | EP | disclosed |
| CN-118451088-A | Method for producing compound, method for producing compound library, and screening method | 国立大学法人东京大学 | 2024-08-06 | — | — | CN | disclosed |
| EP-4353248-A1 | CALCIUM-SENSING RECEPTOR AGONIST COMPOSITION AND APPLICATION THEREOF | Beijing Tuo Jie Biopharmaceutical Co. Ltd. (CN) | 2024-04-17 | — | — | EP | disclosed |
| US-20240094161-A1 | THIN FILM, BIOSENSOR, AND METHOD FOR PRODUCING THEM | THE UNIVERSITY OF TOKYO (JP) | 2024-03-21 | — | — | US | disclosed |
| CN-117500820-A | Hydrochloride of calcium sensitive receptor agonist compound, pharmaceutical composition and application thereof | 北京拓界生物医药科技有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-117295510-A | Composition of calcium sensitive receptor agonist and application thereof | 北京拓界生物医药科技有限公司 | 2023-12-26 | — | — | CN | disclosed |
| EP-4280287-A1 | THIN FILM, BIOSENSOR, AND METHOD FOR MANUFACTURING SAME | The University of Tokyo (JP) | 2023-11-22 | — | — | EP | disclosed |
| CN-116745607-A | Thin film, biosensor, and method for producing the same | 国立大学法人东京大学 | 2023-09-12 | — | — | CN | disclosed |
| WO-2023068296-A1 | METHOD FOR PRODUCING COMPOUNDS, METHOD FOR PRODUCING COMPOUND LIBRARY, COMPOUND LIBRARY, AND SCREENING METHOD | 国立大学法人東京大学 | 2023-04-27 | — | — | WO | disclosed |
| US-20230041996-A1 | CALCIUM-SENSING RECEPTOR AGONIST COMPOUND AND APPLICATION THEREOF | BEIJING TUO JIE BIOPHARMACEUTICAL CO. LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| WO-2022257958-A1 | CALCIUM-SENSING RECEPTOR AGONIST COMPOSITION AND APPLICATION THEREOF | 北京拓界生物医药科技有限公司 | 2022-12-15 | — | — | WO | disclosed |
| WO-2022257940-A1 | HYDROCHLORIDE SALT OF CALCIUM-SENSING RECEPTOR AGONIST COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 北京拓界生物医药科技有限公司 | 2022-12-15 | — | — | WO | disclosed |
| EP-4091623-A1 | CALCIUM-SENSING RECEPTOR AGONIST COMPOUND AND APPLICATION THEREOF | Beijing Tuo Jie Biopharmaceutical Co. Ltd. (CN) | 2022-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250361280-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | CHRM2 4836/4885CHRM4 4802/4885CHRM1 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.